Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor
December 16, 2009
In the post–Human Genome Project era, “personalized medicine” has become a buzzword. Health-care professionals increasingly have access to gene sequence data, with the promise that this information will improve the health of the individual. In the area of breast oncology, the study of genetic markers associated with clinical outcome has been a relative success story.